Welcome to our dedicated page for ACHIEVE LIFE SCIENCES SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Franklin Resources, Inc. and affiliates report beneficial ownership of Achieve Life Sciences, Inc. common stock. Franklin Advisers, Inc. is reported as having sole voting and dispositive power over 8,878,942 shares, representing 8.3% of the common stock.
This position includes 3,925,722 shares issuable upon exercise of warrants. Within this holding, Franklin Biotechnology Discovery Fund has an interest in 5,670,723 shares, or 5.3% of the class. Franklin Resources, its principal shareholders, and subsidiaries disclaim pecuniary interest and do not concede they form a group for Section 13 purposes.
BlackRock, Inc. reports beneficial ownership of common stock of Achieve Life Sciences, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 5,271,391 shares of common stock, representing 5.1% of the class.
BlackRock has sole voting power over 5,188,710 shares and sole dispositive power over 5,271,391 shares, with no shared voting or dispositive power. The shares are held across certain BlackRock business units on behalf of various clients, and no single underlying person is reported to have more than five percent of Achieve Life Sciences’ outstanding common shares.
Vivo Opportunity entities report beneficial ownership of Achieve Life Sciences common stock. Collectively, Vivo Opportunity, LLC and its related funds may be deemed to beneficially own 5,305,640 shares of common stock, equal to 5.0% of the issuer on the filing's stated basis. Several related funds report holdings ranging from 196,424 shares (0.2%) to 2,140,852 shares (2.0%); totals include shares issuable on exercise of warrants and are calculated on 105,410,089 shares outstanding (including certain warrant shares) as of the filing’s stated basis.
Achieve Life Sciences, Inc. amended its certificate of incorporation to increase authorized common stock from 150,000,000 shares to 300,000,000 shares, following approval at its annual meeting of stockholders.
Stockholders elected nine directors, ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
Achieve Life Sciences is asking stockholders to approve four key items at its 2026 virtual annual meeting on July 2, 2026. Stockholders will vote on electing nine directors, ratifying PricewaterhouseCoopers as auditor for 2026, and a non-binding “Say on Pay” vote on executive compensation.
The company also seeks to amend its certificate of incorporation to increase authorized common stock from 150,000,000 to 300,000,000 shares. As of May 15, 2026, 102,659,057 shares were outstanding and all authorized common stock was either issued or reserved, including large warrant and equity plan reserves tied to the June 2025 public offering and April 2026 private placement.
The proxy outlines board structure, committee responsibilities, director independence and compensation, related-party arrangements, and prior financings that raised approximately $45.0 million in June 2025 and $180.0 million in April 2026, largely through common stock, pre-funded warrants and accompanying common warrants.
Achieve Life Sciences director Reid Alexander Waldman received a new stock option grant, giving him the right to buy 47,250 shares of common stock at an exercise price of $5.24 per share. These options vest in substantially equal monthly installments over 36 months starting on May 29, 2026, so the award becomes available gradually as he continues serving the company.
The options expire on May 29, 2036 if not exercised, and this grant brings Waldman’s total reported option holdings from this award to 47,250 derivative securities. The transaction is compensation-related rather than an open-market purchase or sale of existing shares.
ACHIEVE LIFE SCIENCES, INC. reported that director Jeffrey S. Farrow received a grant of stock options. The award covers 47,250 shares of common stock at an exercise price of $5.24 per share, expiring on May 29, 2036. Following the grant, he holds options for 47,250 underlying shares. The options will vest in substantially equal monthly installments over 36 months starting May 29, 2026, as long as he continues providing services to the company on each vesting date.
ACHIEVE LIFE SCIENCES, INC. director Reid Alexander Waldman filed an initial Form 3 reporting his ownership position in the company. The filing shows that no securities are beneficially owned, with 0 shares held directly after the reporting date. This is a disclosure of status rather than a new transaction.
Achieve Life Sciences director Jeffrey S. Farrow has filed an initial Form 3 indicating he currently holds no company securities. The filing lists “No securities are beneficially owned,” with total shares following the reported status shown as 0. This establishes his baseline ownership disclosure as a director of Achieve Life Sciences.